TG THERAPEUTICS INC (TGTX)
US88322Q1085 - Common Stock
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast...
NASDAQ:TGTX stands out as a growth opportunity that won't break the bank.
NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
Noteworthy Wednesday Option Activity: CVNA, AAP, TGTX
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week.
TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results
The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product.
These stocks are moving in today's pre-market session
Stay updated with the stocks that are on the move in Monday's pre-market session.
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million ...
AI Stocks Meta, Oracle Lead Five Names Near Buy Points
Two of the 5 top stocks to watch this week tap the artificial intelligence market.
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Amid the election, and a Fed rate vote, earnings season roars ahead.
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
Conference call to be held Monday, November 4, 2024, at 8:30 AM ET...
RSI Alert: TG Therapeutics (TGTX) Now Oversold
Interesting TGTX Put And Call Options For May 2025
Stock Market Hits Record Highs On Big Fed Rate Cut; Apple, Intel, FedEx In Focus: Weekly Review
TheApple iPhone 16 went on sale amid mixed signals about demand.
IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug
The company unveiled five-year test results for its multiple sclerosis drug, Briumvi.
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate...
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment ...
Interesting TGTX Put And Call Options For November 1st
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations,...
First Week of TGTX October 18th Options Trading